A Panel Discussion among Ten Neurologists
Study Description and Objectives
To conduct a panel discussion among MS specialists to assess the current and future market for Tysabri® (natalizumab). Secondary objectives:
§ Understand current usage patterns for Tysabri, including patient types and lines of therapy
§ Determine patient demand
§ Uncover drivers and barriers for prescribing
§ Gauge expected levels of future prescribing
§ Examine PML risk and the impact any future PML cases would have on use
§ Identify other factors that will impact the Tysabri market, including products in the pipeline
Companies and Products Mentioned in This Report
|
Company |
Ticker Symbol |
Product(s) |
|
Bayer HealthCare Pharmaceuticals |
BAYRY |
Betaseron® (interferon beta-1b) Campath® (alemtuzumab) |
|
Biogen Idec, Inc |
BIIB |
Tysabri® (natalizumab) Avonex® (interferon beta-1a) Rituxan® (rituximab) |
|
EMD Serono, Inc.* |
MKGAF |
Rebif® (interferon beta-1a) |
|
Genentech |
DNA |
Rituxan® (rituximab) |
|
OSI Pharmaceuticals, Inc./EMD Serono, Inc. |
OSIP MKGAF |
Novantrone® (mitoxantrone) |
|
Teva Pharmaceutical Industries Ltd. |
TEVA |
Copaxone® (glatiramer acetate) |
*Affiliate of Merck KGaA
Inclusion Criteria and Panel Details
|
Inclusion Criteria |
§ US-based § Training and board-certification in neurology § 2 to 30 years of experience post-training § From academic and community-based medical centers § Personally treat a high volume of RRMS patients § Prescribe Tysabri and registered in the TOUCH program |
|
Discussion Dates |
June 20, 2008 through June 30, 2008 |
Print Abstract
For additional information on this study or to purchase, please call:
|
Discussion
Neuro |